Sandoz, a Novartis division, announces that it has signed an agreement with Shionogi for commercialization of Rizmoic in the markets of Germany, the UK, and the Netherlands, plus right of first refusal for certain other European markets. Rizmoic, a once-daily 200-microgram oral tablet discovered and developed by Shionogi, is a medicine indicated to treat opioid induced constipation, or OIC, in adult patients previously treated with a laxative. Shionogi announced on February 22 that it had received EU marketing authorization for Rizmoic. Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic in Germany, the UK, and the Netherlands and Shionogi will be responsible for its manufacturing and development. Further details of the deal are not being disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.